N-acetyltransferase 2 phenotype, occupation, and bladder cancer risk: Results from the EPIC cohort

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 2056-2065

  Pesch, Beate ^a   Gawrych, Katarzyna ^a   Rabstein, Sylvia ^b   Weiss, Tobias ^a   Casjens, Swaantje ^a   Rihs, Hans Peter ^a   Ding, Hui ^ai   Angerer, Jürgen ^a   Illig, Thomas ^aj   Klopp, Norman ^aj   Bueno De mesquita, Bas ^f,g   Ros, Martine M ^f   Kaaks, Rudolf ^c   Chang Claude, Jenny ^c   Roswall, Nina ^h   Tjønneland, Anne ^h   Overvad, Kim ⁱ   Clavel Chapelon, Françoise ^j   Boutron Ruault, Marie Christine ^j   Dossus, Laure ^c,j   Boeing, Heiner ^d   Weikert, Steffen ^e   Trichopoulos, Dimitrios ^m,n   Palli, Domenico ^o   Sieri, Sabina ^p   Tumino, Rosario ^q   Panico, Salvatore ^r   Quirós, José Ramón ^t   González, Carlos ^u   Sánchez, Mariá José ^v,w   Dorronsoro, Miren ^x   Navarro, Carmen ^y   Barricarte, Aurelio ^z   Ljungberg, Börje ^aa   Johansson, Mattias ^k   Ulmert, David ^ab,ac,ad   Ehrnström, Roy ^ac   Khaw, Kay Tee ^ae   Wareham, Nick ^af   Key, Timothy J ^ag   Ferrari, Pietro ^l   Romieu, Isabelle ^l   Riboli, Elio ^ah   Brüning, Thomas ^a   Vineis, Paolo ^s,ah   more..

^a INSTITUT DER RUHR UNIVERSITÄT BOCHUM IPA   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

ⁱ Institute of Clinical Medicine   (Denmark)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k Genetic Epidemiology Group   (France)

^l INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^m HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

ⁿ HELLENIC HEALTH FOUNDATION   (Greece)

^o CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q Civile MP Arezzo Hospital   (Italy)

^r UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^s HuGeF Foundation   (Italy)

^t Public Health and Health Planning ^*  (United States)

^u CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^v Andalusian School of Public Health   (Spain)

^w CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^x Public Health Division of Gipuzkoa   (Spain)

^y Murcia Regional Health Authority   (Spain)

^z INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^aa UMEÅ UNIVERSITY   (Sweden)

^ab LUND UNIVERSITY HOSPITAL   (Sweden)

^ac LUND UNIVERSITY   (Sweden)

^ad MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^ae UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^af ADDENBROOKE S HOSPITAL   (United Kingdom)

^ag UNIVERSITY OF OXFORD   (United Kingdom)

^ah IMPERIAL COLLEGE LONDON   (United Kingdom)

^ai ABBOTT GMBH AND CO KG   (Germany)

^aj HANNOVER MEDICAL SCHOOL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINE; ARYLAMINE ACETYLTRANSFERASE; DNA; POLYCYCLIC AROMATIC HYDROCARBON; AMINE; NAT2 PROTEIN, HUMAN;

ACETYLATION; ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD SAMPLING; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC SCREENING; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OCCUPATIONAL EXPOSURE; OCCUPATIONAL HAZARD; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; CASE CONTROL STUDY; ENZYMOLOGY; GENETICS; META ANALYSIS; METABOLISM; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

ACETYLATION; ADULT; AGED; AMINES; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PHENOTYPE; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; URINARY BLADDER NEOPLASMS; YOUNG ADULT;

EID: 84887287349     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0119-T     Document Type: Article

References (56)

1. Vineis P, Pirastu R. Aromatic amines and cancer. Cancer Causes Control 1997;8:346-55.
2. Freudenthal RI, Stephens E, Anderson DP. Determining the potential of aromatic amines to induce cancer of the urinary bladder. Int J Toxicol 1999;18:353-9.
3. Bosetti C, Boffetta P, La Vecchia C. Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: A quantitative review to 2005. Ann Oncol 2007;18:431-46.
4. Lower GM Jr, Nilsson T, Nelson CE, Wolf H, Gamsky TE, Bryan GT. Nacetyltransferase phenotype and risk in urinary bladder cancer: Approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ Health Perspect 1979;29:71-9.
5. Vineis P, Schulte PA. Scientific and ethical aspects of genetic screening of workers for cancer risk: The case of the N-acetyltransferase phenotype. J Clin Epidemiol 1995;48:189-97.
6. Dong LM, Potter JD, White E, Ulrich CM, Cardon LR, Peters U. Genetic susceptibility to cancer: The role of polymorphisms in candidate genes. JAMA 2008;299:2423-36.
7. Garcia-Closas M, Malats N, Silverman D, Dosemeci M, Kogevinas M, Hein DW, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005;366:649-59.
8. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: A meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000;10:115-22.
9. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: A case-series meta-analysis of a geneenvironment interaction. Cancer Epidemiol Biomarkers Prev 2000; 9:461-7.
10. Sanderson S, Salanti G, Higgins J. Joint effects of the N-acetyltransferase 1 and 2 (NAT1 and NAT2) genes and smoking on bladder carcinogenesis: A literature-based systematic HuGE review and evidence synthesis. Am J Epidemiol 2007;166:741-51.
11. Moore LE, Baris DR, Figueroa JD, Garcia-Closas M, Karagas MR, Schwenn MR, et al.GSTM1 null andNAT2 slow acetylation genotypes, smoking intensity and bladder cancer risk: results from the New England bladder cancer study and NAT2 meta-analysis. Carcinogenesis 2011;32:182-9.
12. Carreon T, Ruder AM, Schulte PA, Hayes RB, Rothman N, Waters M, et al. NAT2 slow acetylation and bladder cancer in workers exposed to benzidine. Int J Cancer 2006;118:161-8.
13. Hayes RB, Bi W, Rothman N, Broly F, Caporaso N, Feng P, et al. Nacetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis 1993;14:675-8.
14. Rothman N, Garcia-Closas M, Hein DW. Commentary: Reflections on G. M. Lower and colleagues' 1979 study associating slow acetylator phenotype with urinary bladder cancer: meta-analysis, historical refinements of the hypothesis, and lessons learned. Int J Epidemiol 2007;36:23-8.
15. McGrath M, Michaud D, De Vivo I. Polymorphisms in GSTT1, GSTM1, NAT1 and NAT2 genes and bladder cancer risk in men and women. BMC Cancer 2006;6:239.
16. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, et al. Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2009;125:2643-51.
17. Eble JN, Sauter G, Epstein JI, Sesterhenn I. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.
18. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, et al. MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat 2005;25:232-8.
19. Rabstein S, Unfried K, Ranft U, Illig T, Kolz M, Rihs HP, et al. Variation of the N-acetyltransferase 2 gene in a Romanian and a Kyrgyz population. Cancer Epidemiol Biomarkers Prev 2006;15:138-41.
20. Rihs HP, Spickenheuer A, Heinze E, Pesch B, Raulf-Heimsoth M, Angerer J, et al. Modulation of urinary polycyclic aromatic hydrocarbon metabolites by enzyme polymorphisms in workers of the German Human Bitumen Study. Arch Toxicol 2011;85(Suppl 1):S73-9.
21. Veglia F, Vineis P, Overvad K, Boeing H, Bergmann M, Trichopoulou A, et al. Occupational exposures, environmental tobacco smoke, and lung cancer. Epidemiology 2007;18:769-75.
22. Wakefield J. A Bayesian measure of the probability of false discovery in genetic epidemiology studies. Am J Hum Genet 2007;81:208-27.
23. Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 2002;11:1544-9.
24. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al. Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: A pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001;10:1249-52.
25. Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES. Arylamine N-Acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: A worldwide population survey. PLoS ONE 2011;6:e18507.
26. Sabbagh A, Marin J, Veyssiere C, Lecompte E, Boukouvala S, Poloni ES, et al. Rapid birth-and-death evolution of the xenobiotic metabolizing NAT gene family in vertebrates with evidence of adaptive selection. BMC Evol Biol 2013;13:62.
27. Bauchet M, McEvoy B, Pearson LN, Quillen EE, Sarkisian T, Hovhannesyan K, et al. Measuring European population stratification with microarray genotype data. Am J Hum Genet 2007;80:948-56.
28. Deitz AC, Rothman N, Rebbeck TR, Hayes RB, Chow WH, Zheng W, et al. Impact of misclassification in genotype-exposure interaction studies: example of N-acetyltransferase 2 (NAT2), smoking, and bladder cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1543-6.
29. Bray MS, Boerwinkle E, Doris PA. High-throughput multiplex SNP genotyping with MALDI-TOF mass spectrometry: practice, problems and promise. Hum Mutat 2001;17:296-304.
30. Trikalinos TA, Salanti G, Khoury MJ, Ioannidis JP. Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated genedisease associations. Am J Epidemiol 2006;163:300-9.
31. Rabstein S, Bruning T, Harth V, Fischer HP, Haas S, Weiss T, et al. Nacetyltransferase 2, exposure to aromatic and heterocyclic amines, and receptor-defined breast cancer. Eur J Cancer Prev 2010;19:100-9.
32. Welcome Trust Case Control Consortium. Genome-wide association study of 14, 000 cases of seven common diseases and 3, 000 shared controls. Nature 2007;447:661-78.
33. Sabbagh A, Darlu P. Inferring haplotypes at the NAT2 locus: The computational approach. BMC Genet 2005;6:30.
34. Agundez JA, Golka K, Martinez C, Selinski S, Blaszkewicz M, Garcia- Martin E. Unraveling ambiguous NAT2 genotyping data. Clin Chem 2008;54:1390-4.
35. Garcia-Closas M, Hein DW, Silverman D, Malats N, Yeager M, Jacobs K, et al. A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background. Pharmacogenet Genomics 2011;21:231-6.
36. Selinski S, Blaszkewicz M, Lehmann ML, Ovsiannikov D, Moormann O, Guballa C, et al. Genotyping NAT2 with only two SNPs (rs1041983 and rs1801280) outperforms the tagging SNP rs1495741 and is equivalent to the conventional 7-SNP NAT2 genotype. Pharmacogenet Genomics 2011;21:673-8.
37. Cascorbi I, Roots I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123-7.
38. Gross M, Kruisselbrink T, Anderson K, Lang N, McGovern P, Delongchamp R, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev 1999;8:683-92.
39. Walraven JM, Zang Y, Trent JO, Hein DW. Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2. Curr Drug Metab 2008;9:471-86.
40. Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K. Reinvestigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 2005;79:196-200.
41. Hein DW. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002;506- 7:65-77.
42. Trepanier LA, Ray K, Winand NJ, Spielberg SP, Cribb AE. Cytosolic arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 1997; 54:73-80.
43. Boukouvala S, Fakis G. Arylamine N-acetyltransferases: what we learn from genes and genomes. Drug Metab Rev 2005;37:511-64.
44. Patin E, Barreiro LB, Sabeti PC, Austerlitz F, Luca F, Sajantila A, et al. Deciphering the ancient and complex evolutionary history of human arylamine N-acetyltransferase genes. Am J Hum Genet 2006;78: 423-36.
45. Liu L, Wagner CR, Hanna PE. Isoform-selective inactivation of human arylamine N-acetyltransferases by reactive metabolites of carcinogenic arylamines. Chem Res Toxicol 2009;22:1962-74.
46. Butler MA, Lang NP, Young JF, Caporaso NE, Vineis P, Hayes RB, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2:116-27.
47. Vineis P. A self-fulfilling prophecy: Are we underestimating the role of the environment in gene-environment interaction research? Int J Epidemiol 2004;33:945-6.
48. Kauppinen T, Toikkanen J, Pukkala E. From cross-tabulations to multipurpose exposure information systems: A new job-exposure matrix. Am J Ind Med 1998;33:409-17.
49. Pesch B, Haerting J, Ranft U, Klimpel A, Oelschlagel B, Schill W. Occupational risk factors for urothelial carcinoma: Agent-specific results from a case-control study in Germany. MURC Study Group. Multicenter Urothelial and Renal Cancer. Int J Epidemiol 2000;29: 238-47.
50. Kogevinas M, 't Mannetje A, Cordier S, Ranft U, Gonzalez CA, Vineis P, et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 2003;14:907-14.
51. Pukkala E, Martinsen JI, Lynge E, Gunnarsdottir HK, Sparen P, Tryggvadottir L, et al. Occupation and cancer - follow-up of 15 million people in five Nordic countries. Acta Oncol 2009;48:646-790.
52. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997;8:444-72.
53. IARC monographs on the evaluation of the carcinogenic risks of chemicals to humans. Tobacco Smoke and Involuntary Smoking, Vol. 83. International Agency for Research on Cancer; 2004.
54. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, Frederiksen K, Christensen J, Tjonneland A, et al. Tobacco smoke and bladder cancer-in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2006;119:2412-6.
55. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010; 28:409-28.
56. Bermejo JL, Sundquist J, Hemminki K. Bladder cancer in cancer patients: population-based estimates from a large Swedish study. Br J Cancer 2009;101:1091-9.